Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis
NCT ID: NCT02595359
Last Updated: 2019-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
1000 participants
INTERVENTIONAL
2013-01-31
2018-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis
NCT03363295
Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis
NCT05079854
Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.
NCT02770729
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
NCT03244072
Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial
NCT05162625
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
As endophthalmitis is an infection, it should be preventable by antibiotic treatment.
Prophylactic antibiotic treatment can be given as topical treatment preoperatively, or during surgery directly into the anterior chamber, or as a subconjunctival, or it can be given as topical treatment postoperatively.
The aim of this study was to evaluate the efficacy and safety of the prophylactic effect of intracameral moxifloxacin for prevention of postcataract endophthalmitis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
moxifloxacin intracameral
moxifloxacin injection given at conclusion of cataract intervention
Moxifloxacin
Moxifloxacin intracameral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moxifloxacin
Moxifloxacin intracameral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Has significant ocular co-morbidities in one or both eyes which may include (but is not limited to): advanced glaucoma, advanced or active macular degeneration, Fuchs corneal dystrophy, prior corneal transplantation, advanced diabetic eye disease, history of retinal detachment or any patient that would require billing a complex cataract procedure for any reason
* Has a known history of a condition which causes an immuno-compromised host state
50 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidade Federal de Pernambuco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rodrigo Pessoa Cavalcanti Lira
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodrigo Lira
Role: PRINCIPAL_INVESTIGATOR
Prof
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UFPE Ophthalmology
Recife, Pernambuco, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.